Metamizol Basi

Metamizole sodium, the active ingredient in Metamizol Basi, is a pyrazolone presented as an injectable solution for intramuscular and intravenous use. It treats acute pain, post‑operative pain, fever, and visceral pain in adult patients.

GNH USA supplies Metamizol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, ensuring consistent quality, regulatory compliance and batch‑tested documentation for global distribution.

Metamizole sodium is employed for managing pain and fever through its analgesic and antipyretic actions.

Acute pain: provides rapid relief of moderate to severe pain. Post‑operative pain: reduces pain intensity after surgical procedures. Fever: lowers elevated body temperature. Visceral and colic pain: alleviates spasm‑related abdominal discomfort.

Common Side Effects: - Hypotension: transient drop in blood pressure after injection. - Nausea or vomiting: gastrointestinal upset. - Dizziness or vertigo: sensation of light‑headedness. - Injection site pain: local discomfort at the administration site. - Sweating: increased perspiration. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Anaphylaxis: life‑threatening allergic response. - Severe hypotension: profound blood pressure fall requiring intervention. - Hepatic enzyme elevation: possible liver function abnormalities. - Blood dyscrasias: other serious hematologic abnormalities.

Metamizole sodium requires careful monitoring due to potential hematologic and cardiovascular effects.

Assess blood counts before therapy: monitor for agranulocytosis. Use with caution in renal impairment: adjust monitoring of renal function. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Monitor blood pressure during IV infusion: watch for hypotensive episodes. Pregnancy and lactation: use only if benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metamizole sodium may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: increased risk of bone‑marrow suppression. - ACE inhibitors: may potentiate hypotensive effects. - Other NSAIDs/COX inhibitors: additive renal toxicity risk. - Anticoagulants: heightened bleeding tendency. - Allopurinol: possible increased agranulocytosis risk.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - Antihypertensives: observe for excessive blood‑pressure lowering. - CYP450 inhibitors: potential alteration of drug metabolism. - Other analgesics: enhanced sedation or respiratory depression. - Methotrexate: increased risk of toxicity, monitor levels.